Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel biologic therapies for inflammatory and immunology conditions. Its programs target diseases such as atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease, areas where current treatment options can leave important unmet needs. The company centers its research on antibody-based medicines designed to improve durability, dosing convenience, and therapeutic performance through advanced engineering. Apogee Therapeutics Inc. also explores combination and monotherapy approaches across dermatology, respiratory, and gastroenterology-related indications. Headquartered in Waltham, Massachusetts and founded in 2022, the company plays a role in the biopharmaceutical market by advancing specialized treatments for patients with chronic immune-mediated disorders.
WebsiteOne Letterman Drive
San Francisco, CA, 94129-1492
United States
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee’s promising inflammatory and immunology (I&I) pipeline into AbbVie’s commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its […]
Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.
AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.
AbbVie (ABBV) said Thursday that it has completed its acquisition of Apogee Therapeutics (APGE), val
Investors talking about APGE also mention
| # | Name | Attention |
|---|---|---|
| 1 | Spyre Therapeutics, Inc.SYRE | 0%new |
| 2 | Regenxbio Inc.RGNX | 0%+0 |
| 3 | Abivax SAABVX | 0.01%-0.01 |
| 4 | Nektar TherapeuticsNKTR | 0.08%+0.03 |
| 5 | Invesco Top QQQ ETFQBIG | 0%0 |
| 6 | Janux Therapeutics, Inc.JANX | 0%0 |
| 7 | Revolution Medicines, Inc.RVMD | 0.01%-0.01 |
| 8 | Kymera Therapeutics Inc.KYMR | 0%0 |
| 9 | Edgewise Therapeutics Inc.EWTX | 0%new |
| 10 | Celcuity Inc.CELC | 0%0 |
What share of all stock conversation is about APGE?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% +0 | 0% 0 | 0% +0 |
Of the messages about APGE that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 100% +68.52 | 67.8% -17.61 | ||
| Bearish | — | — | 0% -68.52 | 32.2% +17.61 |
Of the messages about APGE that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 100% | 100% | 87.26% | ||
| Analysts | — | 0% | 0% | 5.43% | ||
| Technical Analysis | — | 0% | 0% | 4.35% | ||
| Controversies | — | 0% | 0% | 0.74% | ||
| Earnings | — | 0% | 0% | 0.07% | ||
| Macro | — | 0% | 0% | 2.15% |
Of the messages about APGE, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 0% | 78.57% | 67.12% | 66.03% | ||
| Newcomers | 100% | 21.43% | 32.88% | 33.97% |